TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03340662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: CYP3A Inhibitor
Study: NCT00569296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: 250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
Study: NCT03340662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: CYP1A2 Inhibitor
Study: NCT03374007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 1mg/kg
Description: single-dose:1mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 3mg/kg
Description: single-dose: 3mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 10mg/kg
Description: single-dose:10mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 1mg/kg, q2w*6
Description: multiple dosing: 1mg/kg, q2w\*6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 3mg/kg, q2w*6
Description: multiple dosing: 3mg/kg, q2w\*6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 10mg/kg, , q2w*6
Description: multiple dosing: 10mg/kg, , q2w\*6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 280mg, q3w
Description: multiple dosing: 280mg, q3w

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection 3mg/kg, q2w
Description: multiple dosing: 3mg/kg, q2w
Study: NCT03123276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: humanized IgG4 PD-1 blocking antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
Study: NCT02758639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wonders & Worries Psychosocial Intervention
Description: Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
Study: NCT02652416

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT03345524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Buddy System
Description: 2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed
Study: NCT02758639

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wonders & Worries Psychosocial Intervention
Description: Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
Study: NCT03345524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)
Study: NCT03022500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab + tremelimumab
Description: Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Study: NCT01940393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Drug administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Drug Administration
Study: NCT05468801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Homeopathic Remedy
Description: An individualized homeopathic remedy selected for each subject according clinical homeopathic parameters will be administered daily in the form of oral globules as an add on to conventional treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus Standard Pharmacologic Treatment
Study: NCT03482115

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET examination with radiopharmaceutical drug [18F] DPA-714
Description: Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection

Intervention type: RADIATION
Group type: OTHER
Intervention: PET examination with radiopharmaceutical drug [18F] DPA-714
Description: Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI examination
Description: MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
Study: NCT03414476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair follicles sampling
Description: The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair follicles sampling
Description: The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
Study: NCT03870165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salmon
Description: Participants will ingest salmon immediately after resistance exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated amino acids and fatty acids
Description: Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
Study: NCT02089607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal Aortic Aneurysm Arm
Description: The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic Arch Aneurysm Arm
Description: The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
Study: NCT00805467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
Study: NCT03305627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short PAP
Description: Perioperative antibiotic prophylaxis for 24h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extended PAP
Description: Perioperative antibiotic prophylaxis for \>48h
Study: NCT00489255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigan®
Description: Oral capsule, 300mg three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule, three times daily
Study: NCT01940393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Drug administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebastine
Description: Drug administration
Study: NCT05159024

Intervention type: DIAGNOSTIC_TEST
Intervention: CRP, PCT, and WBCs trajectories
Description: the levels of CRP, PCT, and WBCs were assessed before surgery and after the onset of leak
Study: NCT02085447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAE-L
Description: Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
Study: NCT02490644

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling 5ml
Study: NCT02387411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval exercise training
Description: High-intensity interval exercise training \[4 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise training
Description: High intensity \[2 reps \* (4 min at 80% VO2peak + 3 min at 50% VO2peak)\] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
Study: NCT01654016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detralex
Description: Detralex 500 mg twice daily for three month prior to surgery
Study: NCT01810757

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard planning radiotherapy
Description: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive planning radiotherapy
Description: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
Study: NCT04457037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells
Study: NCT00972595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron clinical trial formulation
Description: Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
Study: NCT03340662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: CYP3A Inducer
Study: NCT03230448

Intervention type: OTHER
Intervention: questionnaire
Description: after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption

Intervention type: OTHER
Intervention: questionnaire
Description: after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
Study: NCT03342261

Intervention type: DRUG
Intervention: DAA treatment
Description: Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
Study: NCT02052167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methotrexate prefilled pen
Study: NCT03738592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral exploration of spatial hearing performances
Description: Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion.
Study: NCT01940393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: Drug administration
Study: NCT02066129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 44 mcg
Description: Fluticasone is an inhaled corticosteroid
Study: NCT03738592

Intervention type: OTHER
Group type: OTHER
Intervention: behavioral exploration of spatial hearing performances
Description: Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)
Description: For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI).
Study: NCT00972595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron marketed formulation
Description: Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
Study: NCT04671693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PASCA intervention
Description: At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology.
Study: NCT04107909

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic cholecystectomy
Description: Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic cholecystectomy
Description: Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor.
Study: NCT02890784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dasatinib (SPRYCEL®)
Description: Treatment optimization for patients with chronic myeloid leukemia (CML)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib (SPRYCEL®)
Description: Treatment optimization for patients with chronic myeloid leukemia (CML)
Study: NCT01897805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heart-protecting Musk Pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01765335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICaS system
Description: NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
Study: NCT04660279

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dynamic Whole-Body parametric PET/CT
Description: Dynamic whole-body PET/CT imaging protocol
Study: NCT01034956

Intervention type: DEVICE
Intervention: hyaluronic acid or calcium hydroxylapatite filler
Description: Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
Study: NCT04615650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Surgical treatment of suprasyndesmotic ankle fractures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle orthosis
Description: Non-surgical treatment of suprasyndesmotic ankle fractures
Study: NCT03810040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 140 microns denuding pipette
Description: the degranulated needle size was 140 microns

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 150 microns denuding pipette
Description: the degranulated needle size was 150 microns